An examination of the interplay between enterocyte-based metabolism and lymphatic drug transport in the rat

Drug Metabolism and Disposition

Volumn 34, Issue 5, 2006, Pages 729-733

  Trevaskis, Natalie L ^a   Porter, Christopher J H ^a   Charman, William N ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPHENOTANE; CYTOCHROME P450; HALOFANTRINE; KETOCONAZOLE; LIPID; LIPOPROTEIN; LYSOPHOSPHATIDYLCHOLINE; OLEIC ACID;

ANIMAL EXPERIMENT; ARTICLE; CALCULATION; CANNULATION; DRUG METABOLISM; DRUG TRANSPORT; DUODENUM; INTESTINE CELL; INTESTINE LYMPH; ISOTOPE LABELING; LIPID TRANSPORT; LYMPH VESSEL; LYMPHATIC SYSTEM; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SYSTEMIC CIRCULATION; TURNOVER TIME;

ALGORITHMS; ANIMALS; ANTIMALARIALS; CHEMISTRY, PHARMACEUTICAL; DDT; ENTEROCYTES; INSECTICIDES; LYMPHATIC SYSTEM; MALE; PHENANTHRENES; RATS; RATS, SPRAGUE-DAWLEY;

ANIMALIA;

EID: 33645826546     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.105.008102     Document Type: Article

References (13)

1. Charman WN and Stella VJ (1986a) Estimating the maximum potential for intestinal lymphatic transport of lipophilic drug molecules. Int J Pharm 34:175-178.
2. Charman WN and Stella VJ (1986b) Effect of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT. Int J Pharm 33:165-172.
3. Halliday RC, Jones BC, Smith DA, Kitteringham NR, and Park BK (1995) An investigation of the interaction between halofantrine, CYP2D6 and CYP3A4: studies with human liver microsomes and heterologous enzyme expression systems. Br J Clin Pharmacol 40:369-378.
4. Humberstone AJ, Porter CJ, and Charman WN (1996) A physicochemical basis for the effect of food on the absolute oral bioavailability of halofantrine. J Pharm Sci 85:525-529.
5. Khoo SM, Edwards GA, Porter CJ, and Charman WN (2001) A conscious dog model for assessing the absorption, enterocyte-based metabolism and intestinal lymphatic transport of halofantrine. J Pharm Sci 90:1599-1607.
6. Nevin P, Koelsch D, and Mansbach CM (1995) Intracellular triacylglycerol storage pool size changes under different physiological conditions. J Lipid Res 36:2405-2412.
7. Porter CJ and Charman WN (2001a) Intestinal lymphatic drug transport: an update. Adv Drug Deliv Rev 50:61-80.
8. Porter CJ and Charman WN (2001b) Lipid-based formulations for oral administration: opportunities for bioavailability enhancement and lipoprotein targeting of lipophilic drugs. J Recept Signal Transduct Res 21:215-257.
9. Sieber SM, Cohn VH, and Wynn WT (1974) The entry of foreign compounds into the thoracic duct lymph of the rat. Xenobiotica 4:265-284.
10. Tipton AD, Frase S, and Mansbach CM (1989) Isolation and characterization of a mucosal triacylglycerol storage pool undergoing hydrolysis. Am J Physiol 257:871-878.
11. Trevaskis NL, Porter CJ, and Charman WN (2005) Bile increases intestinal lymphatic drug transport in the fasted rat. Pharm Res (NY) 11:1863-1870.
12. Trevaskis NL, Porter CJ, and Charman WN (2006) The size and dynamics of the lymph lipid precursor pool are key determinants of lymphatic drug transport. J Pharmacol Exp Ther 316:881-891.
13. Van Veld PA, Vetter RD, Lee RF, and Patton JS (1987) Dietary fat inhibits the intestinal metabolism of the carcinogen benzo[a]pyrene in fish. J Lipid Res 28:810-817.